Combined inhibition of non-redundant PD-1 and CTLA-4 immune checkpoints, especially in tumors with baseline-negative PD-L1 status, increases infiltration and expansion of the activated (not exhausted) effector T cells in the tumor periphery and triggers unique cellular responses compared with monotherapy [16,17]. The gene discussed is PDCD1; the disease is neoplasm.